Biodexa Pharmaceuticals (BDRX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including GIST, FAP, NMIBC, and T1D.

• Pipeline includes eRapa (licensed from Emtora Biosciences), MTX240 (licensed from Otsuka), and tolimidone, with ongoing Phase 2 and Phase 3 studies.

• Recent strategic shift includes deprioritizing MTX110 and closing the Cardiff laboratory, ceasing investment in drug delivery technologies.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were £8.5 million (actual) and £10.6 million (pro forma as-adjusted).

• Total equity was £11.4 million (actual) and £13.5 million (pro forma as-adjusted).

• Recent offerings raised approximately $0.8 million (Registered Direct Offering), $1.7 million (Warrant Inducement), and $1.0 million (July 2026 Private Placement) before fees and expenses.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises (if any) will be received by the company.

• Funds are intended to support ongoing clinical development and business operations.